Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma
FREMONT, Calif., February 12, 2025--(BUSINESS WIRE)--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline.
"Today, we have aggressively accelerated Tivic's strategic transformation from a single-product, direct-to-consumer company to a diversified therapeutics company—one with a growing pipeline of clinically validated product candidates," said Jennifer Ernst, Chief Executive Officer of Tivic. "Statera's TLR5 immunotherapy program strongly complements our work on non-invasive vagus nerve stimulation, positioning us to address immune and autonomic dysregulation—and associated diseases—through both neural and molecular pathways."
The lead product candidate in the licensing program is a TLR5 agonist, Entolimod for the treatment of acute radiation syndrome (ARS). Market research firm CoherentMI estimates the global acute radiation syndrome (ARS) market to be valued at USD 5.2 billion in 2024 with a compound annual growth rate of five percent from 2024 to 2031. CoherentMI goes on to identify Statera Biopharma as one of the key market leaders.
Entolimod and its immunologically optimized derivative, Entalasta, have been the subject of more than forty animal and human trials and $140 million of prior investment.
The FDA has granted Fast Track and Orphan Drug designation to Entolimod for the prevention or treatment of ARS and to prevent death following a potential lethal dose of total body ionization irradiation during or after a radiation disaster.
"Based on extensive prior research, development and numerous clinical trials of Entolimod, this important immunotherapy drug will now be advanced through the final steps toward a BLA filing and potential FDA approval under the skilled execution of the Tivic team," added Michael K. Handley, Chief Executive Officer of Statera. "We believe this agreement has the potential to provide considerable value for both Statera and Tivic shareholders."
About the TLR5 Immunotherapy Program
TLRs play a key role in the innate immune system. Entolimod's mechanism of action provides unique, highly sought-after attributes in the treatment of radiation-related illness.
For ARS, animal studies have shown a three-fold increase in survival with a single dose 25-hours after exposure to lethal levels of radiation. Entolimod was effective without additional supportive care, showed gastrointestinal protective attributes, and exhibited no dose-limiting toxicity at even the highest dosing levels.
Other studies have shown the potential to address additional applications. Tivic has secured exclusive options to these indications subject to certain milestones and payment conditions. These include:
Immunosenescence - the gradual age-related decline in the immune system's ability to fight infections and respond to vaccines.
Lymphocyte exhaustion – a condition in which immune cells, particularly T cells, become less effective after being exposed to infection, cancer, and/or cancer treatments.
Neutropenia - a condition characterized by an abnormally low number of neutrophils, which can result from chemotherapy, radiation, bone marrow disorders, and certain autoimmune conditions.
Vaccine enhancement – use as a vaccine adjuvant to enhance immune response to vaccines.
Chronic radiation syndrome - a condition caused by long-term exposure to low levels of radiation that gradually damages tissues and organs.
Terms of the Agreement
Under the agreement, Tivic will initially pay Statera $1,200,000 in equity consideration and $300,000 cash to Statera for the use of Entolimod to treat ARS. Tivic can, at its discretion, subsequently add one or more indications, as well as expand its license to include an Entolimod derivative, Entalasta, by exercising the exclusive options granted in the agreement. Tivic has no obligation to exercise such options on any specific timeline or at all; but should it do so, Tivic agrees to fund development of each such indication. Additional future payments will be royalty and milestone-driven, ensuring alignment with the clinical and commercial success of Entolimod and, after exercise of the option granted in the agreement, Entalasta.
Importantly, the structure of the agreement allows Tivic to strategically manage its investment while maximizing potential returns in line with shareholder interests. Select team members of Statera will join Tivic to establish Tivic's biopharmaceutical capabilities and advance product candidates towards commercialization.
The transaction also includes exclusive rights and options for more than sixty patents and patents pending, associated know-how, and ownership of previously manufactured and tested materials.
Additional information about this news, including an informational PowerPoint presentation, will be available at: https://ir.tivichealth.com
Craft Capital Management LLC acted as the sole and exclusive investment banking firm in the transaction.
About Tivic Health
Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows Tivic to target disorders and disease via both neural pathways and molecular approaches.
Tivic Health's first FDA approved product ClearUP™ is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. For more information about Tivic Health, visit: https://ir.tivichealth.com
About Statera Biopharma
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera has a large platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. Statera has clinical and preclinical programs for Crohn's disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis. To learn more about Statera, visit www.staterabiopharma.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tivic's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to Tivic's ability to maintain its Nasdaq listing; the development of Tivic's vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tivic does not undertake an obligation to update or revise any forward-looking statement. Investors should read Tivic's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. All of Tivic's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212860402/en/
Contacts
Investor Contact Information:
Hanover International, Inc.ir@tivichealth.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch
Key Points Tesla's heavy reliance on Elon Musk adds significant leadership risk. Increasing competition from established automakers and Chinese EV makers is pressuring Tesla's dominance. Investors need to be comfortable with Tesla's high valuation. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) has long been the front runner in the electric vehicle (EV) revolution in the U.S. Its innovation, brand strength, and rapid growth have made it a favorite among investors. Yet, despite its impressive track record, there are two big risks that investors should carefully consider before buying Tesla stock today. 1. The Elon Musk factor Elon Musk's leadership is often cited as Tesla's greatest strength -- and, paradoxically, one of its most significant vulnerabilities. Musk's vision and hands-on approach have driven Tesla's technological breakthroughs and ambitious expansion. However, this heavy reliance on a single individual introduces what investors refer to as "key man risk." If Musk were to step back from daily operations or shift his focus to other projects, Tesla might face challenges in maintaining its momentum. Though Tesla's management team has grown stronger, few executives command the same vision, drive, and public attention as Musk. Recently, Musk's increasing involvement in political activities has raised concerns about potential distractions or reputational risks for Tesla. While the company has remained operationally strong, these developments underscore the uncertainty around its future leadership continuity. While Tesla's success lies not only with Musk but also with his team, which has executed well on his vision -- no one can build a trillion-dollar company alone -- there is still no clear successor (or a viable management team) . The silver lining here is that the Tesla board has become more serious about finding one in recent months, largely due to the CEO's active involvement in politics. For investors, this means that Tesla's fortunes remain closely tied to Musk's presence and decisions -- a factor that adds a layer of risk to the investment. 2. Intensifying competition Tesla might have been an early mover in the EV industry, but its dominance is no longer guaranteed. The industry landscape is rapidly evolving, with legacy automakers and new entrants accelerating their electric ambitions. Companies like Ford and General Motors are aggressively expanding their EV lineups. For instance, Ford plans to introduce a $30,000 midsize truck by 2027. That price is significantly lower than the average for an EV, and Ford is investing $5 billion in its EV production to make it happen. GM, on the other hand, is working hard on next-generation battery technologies to improve range, charging performance, and cost. Meanwhile, Chinese manufacturers such as BYD are growing their international footprints, particularly in Europe, where Tesla experienced a nearly 27% sales declinein July 2025. BYD's battery technology, government support, and competitive pricing make it a formidable challenger. In addition, a host of EV start-ups are innovating in battery tech, autonomous driving, and new business models, further intensifying competition. While Tesla is not sitting still -- it is working on becoming the lowest-cost producer by cutting prices to grow sales volume and achieve economies of scale -- there is no guarantee that it can maintain its market share over time. In short, it's no longer the only player in town. What does this mean for investors? Tesla's story remains compelling: It's a pioneer with a powerful brand, innovative products, and potential optionality with some of its long shot bets (robotaxi, humanoid robots, etc). But the key man risk surrounding Musk and the escalating competitive landscape are real concerns that investors can't ignore. If Tesla continues to innovate more rapidly than its rivals, the company could sustain its growth trajectory. However, any leadership changes or slips in market position could hurt the business and its share price. While these two risks don't necessarily call for the sale of the stock, they do mean that investors should think carefully before buying the stock today. Tesla stock trades at a significant premium valuation to other carmakers. For perspective, Tesla has a price-to-sales (P/S) ratio of 12.9, compared to GM's 0.3. Unless you're comfortable with the risks and the high valuation, buying the stock today may not be a prudent decision. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $467,985!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $44,015!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $668,155!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 13, 2025 Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends BYD Company and General Motors. The Motley Fool has a disclosure policy. Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch was originally published by The Motley Fool
Business Insider
32 minutes ago
- Business Insider
3 Economic Reports That Could Affect Your Portfolio This Week, August 18-22, 2025
Stocks ended the week on a soft note, still managing to lock in back-to-back weekly gains. The S&P 500 (SPX) rose 0.94% for the week, and the Nasdaq-100 (NDX) inched up 0.43%. The Dow Jones Industrial Average (DJIA) was the standout, delivering a weekly gain of 1.74%. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. After a red Monday, all three major indexes reached all-time highs on Tuesday. This followed in-line CPI data, which bolstered bets that the Fed would deliver its first rate cut of 2025 in September – traders have priced in nearly a 100% chance of a 25-bps easing. Stocks extended gains on Wednesday: the S&P 500 and Nasdaq hit new ATHs again amid remarks from Treasury Secretary Scott Bessent urging a 50-bps cut based on downward revisions in payroll data. Wall Street analysts began forecasting up to three cuts this year, citing a softer labor market, limited tariff pass-through to consumers, and the appointment of Trump's temporary Fed board pick. But those forecasts were questioned Thursday when PPI, which tracks wholesale price trends, came in hotter than expected, denting sentiment and clouding the Fed outlook. Other economic reports pulled markets in opposing directions: July's industrial production was lackluster – although not recession-bellwether weak – while retail sales beat forecasts, underscoring resilient consumer demand despite high borrowing costs. Meanwhile, the UoM consumer sentiment unexpectedly slipped and inflation expectations rose, muddying the outlook for Fed cuts in September. With mixed inflation and consumer data re-injecting uncertainty into the Fed policy outlook, all eyes now turn to Jackson Hole for the annual confab. Jerome Powell's speech on August 22 is the marquee event, expected to instantly influence markets. A dovish tone could broaden the rally, boosting small caps, rate-sensitive areas, and tech. A hawkish stance – highlighting inflation risks or caution – could trigger sharp corrections and volatility, especially in growth and rate-sensitive sectors. Three Economic Reports Here are three key economic reports that could affect your portfolio this week, in addition to the widely anticipated speech by Jerome Powell at the Jackson Hole Economic Policy Symposium. For a full listing of additional economic reports, check out the TipRanks Economic Calendar. » August Philadelphia Fed Manufacturing Survey – Thursday, 8/21 – This report measures manufacturing conditions in the survey area (Philadelphia, New Jersey, and Delaware) and is considered an accurate leading indicator for two nationwide reports: the Manufacturing PMI and ISM Manufacturing Index. » August S&P Global Manufacturing PMI and Services PMI (preliminary readings) – Friday, 8/22 – PMI indices are leading economic indicators used by economists and analysts to gain timely insights into changing conditions, as the direction and rate of change in PMIs usually precede shifts in the broader economy. » July Existing Home Sales – Friday, 8/22 – This report tracks sales volumes and prices of existing single-family homes, condos, and co-ops nationwide. Existing homes account for over 90% of total U.S. home sales, making this a key measure of housing market health and its influence on overall economic activity.
Fox News
an hour ago
- Fox News
Orange juice sugar cuts proposed by FDA to help citrus growers: What it means for you
The U.S. Food and Drug Administration (FDA) is proposing an update to a decades-old orange juice rule that could give American citrus growers a boost — with little to no change in the taste of the popular breakfast staple, experts say. For the first time since 1963, the agency wants to lower the minimum sugar content required in pasteurized orange juice. The proposal, announced on Aug. 6, would drop the required Brix level — a measure of dissolved solids, mostly natural sugars — from 10.5% to 10%. The shift aligns with the natural Brix levels now present in American oranges and corresponds to about 1 gram less of sugar per 8-ounce serving, from 18 grams to 17 grams, per the FDA. The change stems from a 2022 petition by the Florida Citrus Processors Association and Florida Citrus Mutual in which they said the average Brix level of Florida oranges was 9.7 in 2022–23. The current standard was established in 1963 when Florida oranges averaged 11.8 Brix. Severe weather and citrus greening disease have lowered Brix levels in fruit, forcing producers to import sweeter juice – often from Mexico and Brazil – to blend with theirs in order to meet federal standards, according to the FDA. "For years, we've been wasting beautiful American oranges simply due to an outdated regulation, while relying on a high volume of imports," FDA Commissioner Marty Makary said in a statement. The change would reduce dependency on imports, potentially saving orange producers more than $50 million annually, the agency estimated. Growers could still make higher Brix juice if supplies allow, according to the FDA. Uncle Matt's Organic, which makes a variety of juices, lemonades and iced teas, will not be lowering its Brix levels, co-founder Susan McLean said. "Uncle Matt's Organic orange juice contains no added sugar," she told Fox News Digital. "The naturally occurring sugar content comes directly from the fruit itself, and our Brix is consistently above 11.8, which is well above the minimum threshold." But the Florida-based company supports the FDA's proposal. "The update will allow struggling growers to market their fruit more effectively without compromising transparency or food safety," McLean said. The move is part of the FDA's review of over 250 Standards of Identity (SOIs), federally defined rules that spell out what certain foods must contain, and sometimes how they are made, in order to be marketed under a specific name. "The agency is working to ensure its rules are science-based, relevant and responsive to today's food supply and consumer needs," the FDA said in a statement. A public comment period on the proposed rule is open until Nov. 4. The FDA is also seeking feedback on whether to lower the Brix level further. Shannon Shepp, executive director of the Florida Department of Citrus, which has long supported the Brix adjustment, said the industry is not advocating for eliminating standards. "We support science-based updates that reflect current growing conditions, while protecting Florida oranges, our growers and the future of Florida orange juice," Shepp told Fox News Digital. "These standards are created in a spirit of honesty, so that consumers know exactly what they are getting from properly labeled products." Bryan Quoc Le, a California food scientist and author of the book "150 Food Science Questions Answered," told Fox News Digital the change in sugar content will not greatly alter the overall composition of the orange juice. For more Lifestyle articles, visit "There may be very minor changes in flavor profile, fiber content and other components that come along with orange juice, but ultimately this will not be particularly noticeable from either a health or an industry standpoint," he added. The public health impact would be minimal, agreed Dr. Michael Ednie, a Florida-based doctor who is also a registered dietitian. "Orange juice has been criticized for its sugar content because drinking lots of sugary beverages – including fruit juices – can increase risks of health problems, like diabetes and tooth decay," Ednie told Fox News Digital. Nutrition guidelines already recommend drinking fruit juice in moderation, he noted. "So, the main message for public health stays the same: Orange juice is best enjoyed in reasonable amounts as part of a balanced diet." Fox News Digital reached out to the FDA for comment.
